Pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF), is a chronic progressive and ultimately fatal lung disease of unknown etiology.

Currently, 5 million people worldwide are affected by IPF with an estimated 200, 000 patients in the US.

Very few pharmacological options are available: the median survival time is only 3-5 years following diagnosis.

The Bleomycin-induced Mouse Model has been widely used in scientific studies to model pulmonary fibrosis for evaluation of potential therapy.